{"nctId":"NCT03906136","briefTitle":"AScalate: Treat-to-target in Axial Spondyloarthritis","startDateStruct":{"date":"2019-06-04","type":"ACTUAL"},"conditions":["Axial Spondyloarthritis"],"count":304,"armGroups":[{"label":"TREAT-TO-TARGET (T2T)","type":"EXPERIMENTAL","interventionNames":["Biological: Secukinumab/Adalimumab-Biosimilar"]},{"label":"Standard-of-care (SOC)","type":"ACTIVE_COMPARATOR","interventionNames":["Other: Standard-of-care"]}],"interventions":[{"name":"Secukinumab/Adalimumab-Biosimilar","otherNames":[]},{"name":"Standard-of-care","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosis of Axial Spondyloarthritis, axSpA (either Non-Radiographic Axial Spondyloarthritis or Radiographic Axial Spondyloarthritis) fulfilling the Ankylosing Spondyloarthritis International Society classification criteria for axSpA\n* Active disease as defined by having an Ankylosing Spondylitis Disease Activity Score ≥ 2.1 at Screening and Baseline despite concurrent Non-Steroidal Anti-Inflammatory Drug (NSAID) therapy, or intolerance/contraindication to NSAIDs.\n* Objective signs of inflammation at Screening as defined by: Magnetic Resonance Imaging (MRI) of sacroiliac joints performed up to 3 months prior to screening showing acute inflammatory lesion(s), OR elevated quick C-reactive Protein (CRP) (\\> 5 mg/L), OR MRI showing acute inflammatory lesion(s) in the sacroiliac joints and spine performed during screening period.\n* Inadequate response to NSAIDs\n\nExclusion Criteria:\n\n* Previous exposure to secukinumab or other biologic drug directly targeting Interleukin(IL)-17 or IL-17 receptor.\n* Patients who have previously been treated with Tumor Necrosis Factor Alpha inhibitors (investigational or approved).\n* Patients treated with any cell-depleting therapies.\n* Active ongoing inflammatory diseases or underlying metabolic, hematologic, renal, hepatic, pulmonary, neurologic, endocrine, cardiac, infectious or gastrointestinal conditions, which in the opinion of the investigator immunosuppressed the patient and/or places the patient at unacceptable risk for participation in an immunomodulatory therapy.\n* History of clinically significant liver disease or liver injury\n* History of renal trauma, glomerulonephritis, or patients with one kidney only, or a serum creatinine level exceeding 1.8 mg/dL (159.12 μmol/L).\n* Active systemic infections during the last 2 weeks (exception: common cold) prior to randomization.\n* History of ongoing, chronic or recurrent infectious disease or evidence of tuberculosis (TB) infection\n* Patients positive for human immunodeficiency virus, hepatitis B or hepatitis C\n* Life vaccinations within 6 weeks prior to Baseline or planned vaccination during study participation until 12 weeks after last study treatment administration.\n\nOther protocol-defined inclusion/exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"100 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Patients Achieving an ASAS40 Response at Week 24","description":"Assessment of SpondyloArthritis International Society criteria (ASAS) consists of 4 domains measured on visual analog scales (VAS): 1. Patient's global assessment; 2. Patient's assessment of back pain; 3. Function represented by Bath Ankylosing Spondylitis Functional Index (BASFI) average of 10 questions; 4. Inflammation represented by mean duration and severity of morning stiffness, on the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI). ASAS40 response is defined as an improvement of ≥40% and ≥2 units on a scale of 0 - 10 in at least three of the four ASAS domains and no worsening at all in the remaining domain. A score of 0 indicates less severity; a score of 10 indicates more severity. Percentage was calculated from a logistic regression model: logit(proportion) = treatment + baseline quick C-reactive protein (CRP) + baseline weight.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40.1","spread":null},{"groupId":"OG001","value":"49.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients Achieving an ASAS40 Response at Week 12","description":"Assessment of SpondyloArthritis International Society criteria (ASAS) consists of 4 domains measured on visual analog scales (VAS): 1. Patient's global assessment; 2. Patient's assessment of back pain; 3. Function represented by Bath Ankylosing Spondylitis Functional Index (BASFI) average of 10 questions; 4. Inflammation represented by mean duration and severity of morning stiffness, on the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI). ASAS40 response is defined as an improvement of ≥40% and ≥2 units on a scale of 0 - 10 in at least three of the four ASAS domains and no worsening at all in the remaining domain. A score of 0 indicates less severity; a score of 10 indicates more severity. Percentage was calculated from a logistic regression model: logit(proportion) = treatment + baseline quick C-reactive protein (CRP) + baseline weight.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34.0","spread":null},{"groupId":"OG001","value":"46.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients Achieving ASAS20 Response","description":"Assessment of SpondyloArthritis International Society criteria (ASAS) consist of 4 domains measured on visual analog scales (VAS): 1. Patient's global assessment; 2. Patient's assessment of back pain; 3. Function represented by Bath Ankylosing Spondylitis Functional Index (BASFI) average of 10 questions; 4. Inflammation represented by mean duration and severity of morning stiffness, on the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI). ASAS20 response is defined as an improvement of ≥20% and ≥1 unit on a scale of 0 - 10 in at least three of the four ASAS domains and no worsening at all in the remaining domain. A score of 0 indicates less severity; a score of 10 indicates more severity. Percentage was calculated from a logistic regression model: logit(proportion) = treatment + baseline quick C-reactive protein (CRP) + baseline weight.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51.8","spread":null},{"groupId":"OG001","value":"60.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62.1","spread":null},{"groupId":"OG001","value":"65.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients Achieving ASAS Partial Remission","description":"Assessment of SpondyloArthritis International Society criteria (ASAS): 6 domains (4 main; 2 additional assessment domains): 1. Patient's global assessment measured on a visual analog scale (VAS); 2. Patient's assessment of back pain, measured on a VAS; 3. Function represented by Bath Ankylosing Spondylitis Functional Index (BASFI) average of 10 questions as measured by VAS; 4. Inflammation represented by mean duration and severity of morning stiffness, on the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) as measured by VAS; 5. Spinal mobility represented by the Bath Ankylosing Spondylitis Metrology Index (BASMI) lateral spinal flexion assessment; 6. C-reactive protein (CRP, acute phase reactant).\n\nASAS partial remission: a value not above 2 units in each of the four main domains on a scale of 10. Higher score on VAS = higher severity. Percentage calculated from a logistic regression model: logit(proportion) = treatment + baseline quick CRP + baseline weight.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18.2","spread":null},{"groupId":"OG001","value":"29.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.8","spread":null},{"groupId":"OG001","value":"28.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients Meeting the Ankylosing Spondylitis Disease Activity Score (ASDAS) Definition of Inactive Disease","description":"Parameters used for the ASDAS include spinal pain (Bath Ankylosing Spondylitis Disease Activity Index, BASDAI question 2), the patient's global assessment of disease activity, peripheral pain/swelling (BASDAI question 3), duration of morning stiffness (BASDAI question 6) and C-reactive Protein or Erythrocyte Sedimentation Rate).\n\nThe 3 values selected to separate disease activity states were \\< 1.3 between inactive disease and low disease activity, \\< 2.1 between low disease activity and high disease activity, and \\> 3.5 between high disease activity and very high disease activity. Selected cutoffs for improvement scores were a change of ≥ 1.1 unit for \"minimal clinically important improvement\" and a change of ≥ 2.0 units for \"major improvement\". Percentage was calculated from a logistic regression model: logit(proportion) = treatment + baseline ASDAS + baseline weight.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.8","spread":null},{"groupId":"OG001","value":"33.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.8","spread":null},{"groupId":"OG001","value":"33.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With ASDAS Major Improvement","description":"Parameters used for the ASDAS include spinal pain (Bath Ankylosing Spondylitis Disease Activity Index, BASDAI question 2), the patient's global assessment of disease activity, peripheral pain/swelling (BASDAI question 3), duration of morning stiffness (BASDAI question 6) and C-reactive Protein or Erythrocyte Sedimentation Rate).\n\nThe 3 values selected to separate disease activity states were \\< 1.3 between inactive disease and low disease activity, \\< 2.1 between low disease activity and high disease activity, and \\> 3.5 between high disease activity and very high disease activity. Selected cutoffs for improvement scores were a change of ≥ 1.1 unit for \"minimal clinically important improvement\" and a change of ≥ 2.0 units for \"major improvement\". Percentage was calculated from a logistic regression model: logit(proportion) = treatment + baseline ASDAS + baseline weight.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.8","spread":null},{"groupId":"OG001","value":"25.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.6","spread":null},{"groupId":"OG001","value":"27.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With ASDAS Low Disease Activity","description":"Parameters used for the ASDAS include spinal pain (Bath Ankylosing Spondylitis Disease Activity Index, BASDAI question 2), the patient's global assessment of disease activity, peripheral pain/swelling (BASDAI question 3), duration of morning stiffness (BASDAI question 6) and C-reactive Protein or Erythrocyte Sedimentation Rate).\n\nThe 3 values selected to separate disease activity states were \\< 1.3 between inactive disease and low disease activity, \\< 2.1 between low disease activity and high disease activity, and \\> 3.5 between high disease activity and very high disease activity. Selected cutoffs for improvement scores were a change of ≥ 1.1 unit for \"minimal clinically important improvement\" and a change of ≥ 2.0 units for \"major improvement\". Percentage was calculated from a logistic regression model: logit(proportion) = treatment + baseline ASDAS + baseline weight.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46.5","spread":null},{"groupId":"OG001","value":"57.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.4","spread":null},{"groupId":"OG001","value":"57.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients Achieving the Bath Ankylosing Spondylitis Disease Activity Index Response 50% (BASDAI 50) at Week 12 and Week 24","description":"The BASDAI consists of a 0 through 10 scale (0 being no problem and 10 being the worst problem, captured as a continuous VAS), which is used to answer 6 questions pertaining to the 5 major symptoms of the disease. BASDAI 50 response is defined as at least 50% improvement (decrease) in total BASDAI score.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38.0","spread":null},{"groupId":"OG001","value":"42.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42.5","spread":null},{"groupId":"OG001","value":"42.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI)","description":"The Bath Ankylosing Spondylitis Functional Index (BASFI) is a set of 10 questions designed to determine the degree of functional limitation in those patients with AS. The 10 questions were chosen with major input from patients with AS. The first 8 questions consider activities related to functional anatomy. The final 2 questions assess the patients' ability to cope with everyday life. A 0 through 10 scale (captured as a continuous VAS) is used to answer the questions. The mean of the 10 scales gives the BASFI score - a value between 0 and 10. A higher score on the VAS signifies higher severity.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.69","spread":null},{"groupId":"OG001","value":"-1.99","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.97","spread":null},{"groupId":"OG001","value":"-2.33","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Bath Ankylosing Spondylitis Metrology Index (BASMI)","description":"BASMI measures the range of motion based on five clinical measurements: 1) cervical rotation, 2) tragus to wall distance, 3) lumbar side flexion, 4) lumbar flexion (modified Schober's) and 5) intermalleolar distance. BASMI 0 = indicates mild disease involvement, 1 = moderate disease, and 2 = severe disease involvement. The results for cervical rotation and lumbar side flexion are the means of the left and right measurements. Scoring range 0-10. The higher the BASMI score, the more severe was the subject's limitation of movement.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.32","spread":null},{"groupId":"OG001","value":"-0.38","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.41","spread":null},{"groupId":"OG001","value":"-0.35","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Chest Expansion","description":"Chest expansion is measured as the cervical rotation angle (in degrees).","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.46","spread":null},{"groupId":"OG001","value":"1.35","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.47","spread":null},{"groupId":"OG001","value":"0.57","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the ASQoL (Ankylosing Spondylitis Quality of Life Instrument)","description":"The Ankylosing Spondylitis Quality of Life scores (ASQoL) is a self-administered questionnaire designed to assess health-related quality of life in adult patients with Ankylosing Spondylitis. The ASQoL contains 18 items with a dichotomous yes/no response option. A single point is assigned for each \"yes\" response and no points for each \"no\" response resulting in overall scores that range from 0 (least severity) to 18 (highest severity). As such, lower score indicate better quality of life. Items include an assessment of mobility/energy, self-care and mood/emotion. The recall period is \"at the moment,\" and the measure requires approximately 6 minutes to complete.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.52","spread":null},{"groupId":"OG001","value":"-3.39","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.21","spread":null},{"groupId":"OG001","value":"-3.84","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in ASAS-HI (Ankylosing Spondyloarthritis International Society Health Index)","description":"The ASAS-HI is a disease-specific questionnaire that was developed based on the comprehensive International Classification of Functioning, Disability and Health Core Set (also known as the ICF Core Set) for AS. The ASAS HI is a linear composite measure and contains 17 items (dichotomous response option: \"I agree\" and \"I do not agree\"), which cover most of the ICF Core Set. The ASAS HI contains items addressing categories of pain, emotional functions, sleep, sexual function, mobility, self-care, and community life. The total sum of the ASAS HI ranges from 0 to 17, with a lower score indicating a better health status. In addition, the Environmental Factor (EF) Item Set contains items addressing categories of support/relationships, attitudes and health services. The EF Item Set contains 9 dichotomous items with an identical response option but without a sum score because of its multidimensional nature.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.55","spread":null},{"groupId":"OG001","value":"-2.81","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.24","spread":null},{"groupId":"OG001","value":"-3.07","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Global Disease Assessment (Patient)","description":"The patient's global assessment of disease activity was performed using a 100 mm (visual analog scale) VAS, ranging from not severe (0 mm) to very severe (100 mm), in response to the question, \"How active was your disease on average during the last week?\" A higher score indicates more disease activity.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.95","spread":null},{"groupId":"OG001","value":"-3.12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.27","spread":null},{"groupId":"OG001","value":"-3.48","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Global Disease Assessment (Physician)","description":"The physician's global assessment of disease activity was performed using a 100 mm VAS, ranging from not severe (0 mm) to very severe (100 mm), in response to the question, \"Considering all the ways the disease affects your patient, draw a line on the scale for how well his or her condition is today.\" To enhance objectivity, the physician must not be aware of the specific patient's global assessment of disease activity when performing his own assessment on that patient. A higher score indicates more disease activity.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"90% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-32.46","spread":null},{"groupId":"OG001","value":"-36.96","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-35.81","spread":null},{"groupId":"OG001","value":"-38.54","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":10,"n":190},"commonTop":["Nasopharyngitis","Diarrhoea","Headache","Nausea","Upper respiratory tract infection"]}}}